Vectron Biosolutions Obtains Strong Results for Biosimilar Production
Vectron Biosolutions recently announced they have obtained strong results for manufacture of selected biosimilar proteins using its proprietary E. coli expression technology. The study was conducted side-by-side with other expression technologies, and Vectron’s technology produced higher soluble and/or insoluble yields for seven out of 10 tested biosimilar proteins. The increase in yield was 2 to 25 times compared to the best conventional technology.
The biosimilar proteins that were produced more efficiently with Vectron’s technology than with other technologies were human growth hormone, interferon beta-1b, TNF alpha-1a, IGF-1, insulin, IL-2, and IL-1RA.
“Demonstrating that our technology is superior for manufacture of many valuable therapeutic proteins is a major milestone for us,” saidd Trond Erik Vee Aune, CEO of Vectron Biosolutions AS. “Significant increases in soluble and insoluble yields translate directly to large savings in cost of goods for our pharmaceutical partners, especially in the highly competitive biosimilars market, where cost-efficient manufacturing processes are essential. In addition, demonstrating that our technology can be used to obtain many-fold higher titers means our services and technology is highly suitable for new therapeutic proteins being developed, especially those in which low solubility and/or low yields are a complicating issue.”
Through a combination of experienced life science researchers, state-of-the-art laboratory facilities, a proprietary technology platform, and competent management, Vectron Biosolutions AS supplies the pharmaceutical industry with state-of-the-art technology and solutions for manufacture of recombinant proteins in E. coli and other bacteria.
Total Page Views: 912
